peppercalc.com · research use only
Peptide Protocol

CJC-1295 No DAC: pulsatile GHRH for natural GH peaks.

Modified GRF 1-29. Short-acting GHRH analog designed to stack with Ipamorelin for synergistic GH release.

Open Calculator 🌶️ All Protocols →
peppercalc.com · research use only
100–200 mcg
Daily Dose
8–12 wks on / 4 off
Cycle
SubQ
Route
2–3× daily
Frequency
Overview

What is CJC-1295 No DAC?

Modified GRF 1-29 is produced by substituting four amino acids in native GHRH(1-29) to resist enzymatic degradation while preserving full receptor activity. The result is a peptide with a half-life of approximately 30 minutes — long enough for a meaningful pituitary signal, short enough to produce discrete pulses rather than sustained receptor activation.

The combination of CJC-1295 No DAC + Ipamorelin is among the most studied GH-optimization stacks in peptide research. GHRH analogs prime the pituitary, while GHRPs like Ipamorelin trigger the release — producing a GH pulse roughly 2–10× greater than either compound alone. Timing around fasting states is critical for maximal effect.

🔬
GHRH Receptor Activation
Binds pituitary GHRH receptors (GHRHR) to prime GH-producing somatotrophs, directly stimulating GH synthesis and vesicle preparation.
⏱️
Short Half-Life Advantage
~30-minute active window mimics natural GHRH pulse, avoiding continuous receptor stimulation that leads to desensitization with DAC formulations.
Ipamorelin / GHRP Synergy
GHRH + GHRP combination produces multiplicative GH pulses. GHRH fills the 'gas tank'; the GHRP 'pulls the trigger' — synergy is well-documented.
📈
Downstream IGF-1 Production
GH stimulation leads to hepatic IGF-1 synthesis, driving the anabolic, anti-aging, and recovery effects associated with GH axis optimization.
Dosing Protocol

Dosing Schedule

Parameters documented in published preclinical and clinical research.

⚠️ Research use only. The following documents parameters from published preclinical and clinical research. Not medical advice. Not for human consumption. Consult a licensed healthcare professional before any use.
PhaseDoseFrequencyDurationNotes
Start100 mcgOnce daily (bedtime)Days 1–7Tolerance assessment. Always inject fasted (2+ hrs from food).
Working dose (solo)100–200 mcgTwice dailyWeeks 2–8AM fasted + 30 min before bed. Effective solo but optimal when stacked.
Stack dose100 mcg standard2–3× dailyWeeks 2–12Inject simultaneously with 200 mcg Ipamorelin. Same syringe or separate — both work.
Off cycle4 weeksRest before restarting.
Safety Profile

Safety & Side Effects

✓ Generally Well Tolerated
Very well-tolerated in research settings
No significant hormonal disruption beyond GH/IGF-1 axis
Short half-life preserves pulsatile physiology
Synergistic with GHRPs — allows lower individual doses
⚠ Potential Concerns
Completely blunted if injected fed / with elevated glucose
WADA S2 prohibited
Water retention and joint aches possible at higher doses
Must be refrigerated after reconstitution
⚠️
Research use onlyThis page is an educational reference. None of this constitutes medical advice. Consult a qualified professional before any use. All compounds are for research purposes only.
Evidence Base

Academic References

  1. [1]
    Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 91(3):799–805. PubMed ↗
  2. [2]
    Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 91(12):4792–4797. PubMed ↗
  3. [3]
    Bowers CY, Sartor AO, Reynolds GA, Badger TM. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 128(4):2027–2035. PubMed ↗
Recommended Source
Source your compounds at White Market Peptides
Use code PEPPERCALC10 for 10% off + free 2-day shipping over $200
Shop Now →